In alignment with professional recommendations, GLP-1 RAs are prioritized in patients with established atherosclerotic cardiovascular disease (such as coronary artery disease, stroke, or peripheral artery disease) and significant excess body weight. This evidence concerns the gene GLP1R and stroke disorder.